论文部分内容阅读
目的:观察诺和锐30治疗2型糖尿病的临床疗效、依从性。方法:将60例2型糖尿病患者随机分为两组,治疗组30例用诺和锐30,对照组30例用诺和灵30R,均采用早、晚餐前两次皮下注射,诺和锐为餐前立刻注射,诺和灵30R为餐前30min注射,观察12周。分别记录空腹、餐后2h血糖、糖化血红蛋白、低血糖发生率、胰岛素用量。结果:①两组治疗后空腹血糖、餐后2h血糖及糖化血红蛋白均明显下降(P<0.01),但诺和锐30组的餐后血糖、空腹血糖下降更明显(P<0.05);②诺和锐30组低血糖发生率明显低于诺和灵30R组。结论:诺和锐30能更为平稳地降低2型糖尿病的血糖水平,尤其是餐后血糖,且安全性好,依从性好。
Objective: To observe the clinical efficacy and compliance of Novo-Rui 30 in the treatment of type 2 diabetes mellitus. Methods: Sixty patients with type 2 diabetes mellitus were randomly divided into two groups. 30 cases in the treatment group were treated with NovoRui 30 and 30 cases in the control group were treated with NovoRed 30R. Both of them were injected subcutaneously twice before morning and evening, Immediately before meals, Novo-30R was given 30 minutes before meals for 12 weeks. Fasting, postprandial 2h blood glucose, glycosylated hemoglobin, the incidence of hypoglycemia, insulin dosage were recorded. Results: ①The fasting blood glucose, postprandial 2h blood glucose and HbA1c decreased significantly (P <0.01), but the postprandial blood glucose and fasting blood glucose decreased significantly in Novo Rui 30 group (P <0.05) The incidence of hypoglycemia in Rui 30 group was significantly lower than that in Noro Ling 30R group. Conclusions: Novo Rui 30 can lower the blood sugar level of type 2 diabetes more smoothly, especially the postprandial blood glucose, and it has good safety and good compliance.